Back to Journals » Drug Design, Development and Therapy » Volume 9

A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer

Authors Shi H, Guo J, Li C, Wang Z

Received 17 June 2015

Accepted for publication 28 July 2015

Published 31 August 2015 Volume 2015:9 Pages 4989—4996

DOI https://doi.org/10.2147/DDDT.S90670

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Shu-Feng Zhou


Huan Shi,* Jun Guo,* Changzheng Li, Zhehai Wang

Department of Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China

*These authors contributed equally to this work

Abstract: Lung cancer remains the leading common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80% of all cases. To date, platinum-based doublet chemotherapy is the cornerstone of first-line therapy. However, these agents have limited use in patients who have relapsed and have metastatic disease. Therefore, novel strategies are required to improve the clinical outcome. Folate receptor alpha (FRA) is overexpressed in the majority of NSCLC, particularly in lung adenocarcinomas. FRA is largely absent from normal tissue, making it an attractive therapeutic target. In this review, we discuss FRA expression in NSCLC, conjugated FRA agents, monoclonal antibody, and FRA-specific T-cell-based therapeutic strategies aiming to improve the cure rate of FRA-expressing NSCLC.

Keywords: folate receptor alpha, lung cancer, immunotherapy
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]